Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Sep 21 - Sep 26
Market Segmentation Drug Class Insights (Revenue, USD Bn, 2021 - 2033) Exenatide Liraglutide Dulaglutide Lixisenatide Albiglutide Semaglutide Route of Administration Insights (Revenue, USD Bn, 2021 - 2033) Parenteral Oral Application Insights (Revenue, USD Bn, 2021 - 2033) Type 2 Diabetes Mellitus Obesity Liver Cirrhosis Non-alcoholic Steatohepatitis Others Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033) Hospital Pharmacies Retail Pharmacies Online Pharmacies Regional Insights (Revenue, USD Bn, 2021 - 2033) North America U.S
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist
For example, some people find that they eat less on a GLP-1, but theyre not improving their health because theyre not exercising
To find the proportion of ESI enrollees with a prescription for GLP-1 drugs, outpatient pharmaceutical claims from 2012 to 2022 in the Merative MarketScan Commercial Database were used
June 6, 2024
It showed: Average total weight loss : 28.3% TBW with surgery vs
US$ 22.55
US$ 24.96
US$ 28.44
US$ 27.59
